Pharma & Biotech Global Week in Review 11 August 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs)

Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz)

Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging novelty: King Pharmaceuticals, Inc v Eon Labs, Inc and Elan Pharmaceuticals, Inc (Patently-O) (Inventive Step)

US: Gene patents on appeal: ACLU’s recusal motion: AMP v USPTO (Patently-O) (Patent Docs)

Nexavar (Sorafenib) – India: Patent linkage hearing at Supreme Court adjourned: Bayer v Union of India/Cipla (Generic Pharmaceuticals and IP) (Spicy IP)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Coverage of anti-counterfeit policy debate varies widely across global media (IP Watch)

WHO declares flu pandemic over; experts behind response to be revealed (IP Watch)

Australia: TGA to implement alert system for new ARTG registrations (IP Whiteboard)

EU: Final petition of the Advocate-General / Jodosulfuron- SPC for plant protection products (EPLAW)

India: Parliamentary Committee on Health tables report on issues relating to availability of generic medicines (Spicy IP)

Peru: Peruvian Anti-Biopiracy Commission seems to work (IP tango)

US: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs)

US: Pharma and software companies file joint amicus brief in Therasense case (Patent Docs)

US: BIO files amicus brief in Therasense case (Patent Docs)

US: Therasense, Inc v Becton, Dickinson & Co – briefing schedule update (Patent Docs)

US: Gene patents on appeal: ACLU’s recusal motion: AMP v USPTO (Patently-O) (Patent Docs)

US: Illumina, Solexa file patent infringement complaint against Complete Genomics based on manufacture and sale of Complete Genomic Analysis Platform products and services (Patent Docs)

US: OptiGen files patent infringement complaint against Animal Genetics based on sale, use of testing methods for Progressive Rod-Cone Degeneration (Patent Docs)

US: Eben Moglen on Bilski, software patents and big pharma (The Prior Art)

US: 180-day exclusivity – from Abacavir sulphate to zolpidem tartrate (FDA Law Blog)

US: Update – Generic drug labeling carve-out citizen petition scorecard (FDA Law Blog)

US: Senator Brownback introduces the Creating Hope Act of 2010; Bill would change the priority review voucher program and extend it to applications for rare pediatric diseases (FDA Law Blog)

US: Pay-for-delay provision added to Senate Appropriations Bill (Patent Docs)

 

Products

Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz)

Antara (Fenofibrate) – US: Lupin files patent infringement suit against Ranbaxy following Para IV challenge (Patent Docs)

Fosamax (Alendronate) – Israel: Merck’s patent application for once-weekly Alendronate successfully opposed in Israel (The IP Factor)

Gemzar (Gemcitabine) – US: Eli Lilly loses method patent after the use was disclosed in an earlier patent: Sun Pharmaceutical Industries v Eli Lilly and Co (Patent Baristas)

Gynazole (Butoconazole) – US: KV Pharmaceutical sues Perrigo Israel claiming infringement of Gynozole patent in response to Para IV certification (IP Factor) (Patent Docs)

Nexavar (Sorafenib) – India: Patent linkage hearing at Supreme Court adjourned: Bayer v Union of India/Cipla (Generic Pharmaceuticals and IP) (Spicy IP)

Relpax (Eletriptan) – US: Pfizer files patent infringement suit against Teva following Para IV certification (Patent Docs)

Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging novelty: King Pharmaceuticals, Inc v Eon Labs, Inc and Elan Pharmaceuticals, Inc (Patently-O) (Inventive Step)

Taxotere (Docetaxel) – New Zealand: Aventis refused injunction in New Zealand targeting generic Docetaxel: Aventis Pharma SA v Pharmaco (NZ) Ltd (Patentology)

Welchol (Colesevelam) – US: Daiichi Sankyo, Genzyme file patent infringement complaint against Lupin following Para IV challenge (Patent Docs)

2 Comments on “Pharma & Biotech Global Week in Review 11 August 2010 from IP Think Tank

  1. I have been looking for information on this very topic and I am pleased to say that I found this blog to be concise and to the point. I appreciate that very much.

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: